IL-10 antibody

Catalog No. ABIN1177281

Product Details anti-IL-10 Antibody

Target: IL-10 (IL10) (Interleukin 10 (IL10))

Reactivity: Human, Virus

Host: Rat

Clonality: Monoclonal

Conjugate: This IL-10 antibody is un-conjugated

Application: ELISA, Neutralization (Neut), Intracellular Staining (ICS)

Brand: BD Pharmingen™

Characteristics: Neutralization Activity: This antibody has been reported to be useful for the neutralization of recombinant human IL-10. Neutralization activity may be measured with a proliferation assay using 5 ng/mL recombinant human IL-10 (Cat. No. 554611), co-stimulated with 50 pg/mL recombinant mouse IL-4 (Cat. No. 550067), to stimulate MC/9 or D36 cells as indicator cells (i.e preincubation of the antibody with recombinant human IL-10 for 60 min)
50% Neutralization (ND50) at 1 - 20 ng/mL
>95% Neutralization at 25 - 100 ng/mL

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Sterility: 0.2 μm filtered

Endotoxin Level: Endotoxin level is ≤ 0.01 EU/μg (≤ 0.001 ng/μg) of protein as determined by the LAL assay.

Immunogen: Recombinant Human IL-10

Clone: JES3-19F1

Isotype: IgG2a

Application Details

Application Notes: ELISA: The purified format of the JES3-19F1 antibody (Cat. No. 554705) has been reported to be useful as a capture antibody in sandwich ELISA for human IL-10. Purified JES3-19F1 antibody can be paired with the biotinylated JES3-12G8 antibody (Cat. No. 554499) and with recombinant human IL-10 (Cat. No. 554611) as the standard. Purified JES3-19F1 antibody should be titrated to determine the optimal concentration for ELISA capture. An appropriate range of concentrations for the human IL-10 standard for obtaining a linear standard curve is 15 pg/mL to 2000 pg/mL. For testing human IL-10 in complex biological fluids such as serum or plasma, the BD OptEIA™ Human IL-10 ELISA Set (Cat. No. 555157) or Kit (Cat. No. 550613) is recommended.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1.0 mg/mL

Buffer: No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2μm sterile filtered.

Preservative: Azide free

Storage: 4 °C

Storage Comment: Store undiluted at 4°C. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

References for anti-IL-10 antibody (ABIN1177281)

Prussin, Metcalfe: "Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies." in: Journal of immunological methods, Vol. 188, Issue 1, pp. 117-28, (1996) (PubMed).

Andersson, Christensen, Marker, Thomsen: "Changes in cell adhesion molecule expression on T cells associated with systemic virus infection." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 152, Issue 3, pp. 1237-45, (1994) (PubMed).

Schlaak, Schmitt, Hüls, Meyer zum Büschenfelde, Fleischer: "A sensitive and specific bioassay for the detection of human interleukin-10." in: Journal of immunological methods, Vol. 168, Issue 1, pp. 49-54, (1994) (PubMed).

DAndrea, Aste-Amezaga, Valiante, Ma, Kubin, Trinchieri: "Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells." in: The Journal of experimental medicine, Vol. 178, Issue 3, pp. 1041-8, (1993) (PubMed).

Target Details for IL-10

Target: IL-10 (IL10) (Interleukin 10 (IL10))

Alternative Name: IL-10 (IL10 Products)

Synonyms: CSIF antibody, GVHDS antibody, IL-10 antibody, IL10A antibody, TGIF antibody, Il-10 antibody, IL10X antibody, interleukin 10 antibody, IL10 antibody, Il10 antibody

Background: The JES3-19F1 antibody reacts with human (IL-10). The immunogen used to generate the JES3-19F1 hybridoma was recombinant human IL-10 expressed in COS cells. This is a neutralizing antibody. This antibody also reacts with viral IL-10.

Pathways: Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Maintenance of Protein Location, Cancer Immune Checkpoints